{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:14:10Z","timestamp":1794554050318,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gut microbiota alterations in Parkinson\u2019s disease (PD) have been found in several studies and are suggested to contribute to the pathogenesis of PD. However, previous results could not be adequately adjusted for a potential confounding effect of PD medication and disease duration, as almost all PD participants were already using dopaminergic medication and were included several years after diagnosis. Here, the gut microbiome composition of treatment-naive de novo PD subjects was assessed compared to healthy controls (HC) in two large independent case-control cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009136 and 56 PD,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200985 and 87 HC), using 16S-sequencing of fecal samples. Relevant variables such as technical batches, diet and constipation were assessed for their potential effects. Overall gut microbiome composition differed between PD and HC in both cohorts, suggesting gut microbiome alterations are already present in de novo PD subjects at the time of diagnosis, without the possible confounding effect of dopaminergic medication. Although no differentially abundant taxon could be replicated in both cohorts, multiple short chain fatty acids (SCFA) producing taxa were decreased in PD in both cohorts. In particular, several taxa belonging to the family Lachnospiraceae were decreased in abundance. Fewer taxonomic differences were found compared to previous studies, indicating smaller effect sizes in de novo PD.\n                  <\/jats:p>","DOI":"10.1038\/s41531-022-00395-8","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T08:22:11Z","timestamp":1665390131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Fecal microbiome alterations in treatment-naive de novo Parkinson\u2019s disease"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-1771","authenticated-orcid":false,"given":"Jeffrey M.","family":"Boertien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Murtom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A. B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sygrid","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas H.","family":"Mertsalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-1254","authenticated-orcid":false,"given":"Reeta","family":"Levo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Nojonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"M\u00e4kinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Jaakkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0923-1254","authenticated-orcid":false,"given":"Lars","family":"Paulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-8752","authenticated-orcid":false,"given":"Eero","family":"Pekkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-7093","authenticated-orcid":false,"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3947-4778","authenticated-orcid":false,"given":"Petri","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9502-7131","authenticated-orcid":false,"given":"Filip","family":"Scheperjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PPNN Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Verwey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. H.","family":"Langedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Oomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J. A. M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Wieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J. A.","family":"van den Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"van Steenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Duyff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"van Amerongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S. S.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K. L.","family":"Polman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. T.","family":"Zwartbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"van Kesteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Braakhekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E. S.","family":"Hartono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ybema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. E.","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J. H.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. T. H.","family":"Oen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mondria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Holscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A. E.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W. F.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Boekestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Teune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J. L.","family":"Orsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"395_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"395_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/mds.25445","volume":"28","author":"RB Postuma","year":"2013","unstructured":"Postuma, R. B., Gagnon, J.-F., Pelletier, A. & Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson\u2019s disease and dementia with Lewy bodies. Mov. Disord. 28, 597\u2013604 (2013).","journal-title":"Mov. Disord."},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","volume":"73","author":"R Savica","year":"2009","unstructured":"Savica, R. et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73, 1752\u20131758 (2009).","journal-title":"Neurology"},{"key":"395_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg, D. et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 30, 1600\u20131611 (2015).","journal-title":"Mov. Disord."},{"key":"395_CR5","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.3233\/JPD-191707","volume":"9","author":"SCD Van Ijzendoorn","year":"2019","unstructured":"Van Ijzendoorn, S. C. D. & Derkinderen, P. The intestinal barrier in Parkinson\u2019s disease: current state of knowledge. J. Parkinson\u2019s Dis. 9, S323\u2013S329 (2019).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"395_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. & Borghammer, P. Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940\u2013949 (2016).","journal-title":"Ann. Neurol."},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"395_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep34477","volume":"6","author":"SG Chen","year":"2016","unstructured":"Chen, S. G. et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 6, 34477 (2016).","journal-title":"Sci. Rep."},{"key":"395_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.celrep.2019.12.078","volume":"30","author":"ME Goya","year":"2020","unstructured":"Goya, M. E. et al. Probiotic Bacillus subtilis protects against \u03b1-synuclein aggregation in C. elegans. Cell Rep. 30, 367\u2013380.e7 (2020).","journal-title":"Cell Rep."},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469\u20131480.e12 (2016).","journal-title":"Cell"},{"key":"395_CR11","doi-asserted-by":"publisher","unstructured":"Boertien, J. M., Pereira, P. A. B., Aho, V. T. E. & Scheperjans, F. Increasing comparability and utility of gut microbiome studies in Parkinson\u2019s disease: a systematic review. J. Parkinsons. Dis. 1\u201315 (2019). https:\/\/doi.org\/10.3233\/JPD-191711.","DOI":"10.3233\/JPD-191711"},{"key":"395_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans, F. et al. Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov. Disord. 30, 350\u2013358 (2015).","journal-title":"Mov. Disord."},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","volume":"44","author":"VTE Aho","year":"2019","unstructured":"Aho, V. T. E. et al. Gut microbiota in Parkinson\u2019s disease: temporal stability and relations to disease progression. EBioMedicine 44, 691\u2013707 (2019).","journal-title":"EBioMedicine"},{"key":"395_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-020-0112-6","volume":"6","author":"ZD Wallen","year":"2020","unstructured":"Wallen, Z. D. et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. npj Park. Dis. 6, 11 (2020).","journal-title":"npj Park. Dis."},{"key":"395_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. npj Park. Dis. 7, 1\u201313 (2021).","journal-title":"npj Park. Dis."},{"key":"395_CR16","doi-asserted-by":"crossref","unstructured":"Weis, S. et al. Effect of Parkinson\u2019s disease and related medications on the composition of the fecal bacterial microbiota. npj Park. Dis. 5, 28 (2019).","DOI":"10.1038\/s41531-019-0100-x"},{"key":"395_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns, E. M. et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739\u2013749 (2017).","journal-title":"Mov. Disord."},{"key":"395_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41564-020-0743-8","volume":"5","author":"DA Hughes","year":"2020","unstructured":"Hughes, D. A. et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. Nat. Microbiol. 5, 1079\u20131087 (2020).","journal-title":"Nat. Microbiol."},{"key":"395_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mds.27581","volume":"34","author":"M Barichella","year":"2019","unstructured":"Barichella, M. et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Mov. Disord. 34, 396\u2013405 (2019).","journal-title":"Mov. Disord."},{"key":"395_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/mds.27105","volume":"33","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart, A. et al. The nasal and gut microbiome in Parkinson\u2019s disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88\u201398 (2018).","journal-title":"Mov. Disord."},{"key":"395_CR21","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ana.26128","volume":"90","author":"S Heinzel","year":"2021","unstructured":"Heinzel, S. et al. Retraction to: gut microbiome signatures of risk and prodromal markers of Parkinson disease (Annals of Neurology, (2020), 88, 2, (320-331), 10.1002\/ana.26151). Ann. Neurol. 90, E1\u2013E12 (2021).","journal-title":"Ann. Neurol."},{"key":"395_CR22","doi-asserted-by":"crossref","unstructured":"Nishiwaki, H. et al. Short-chain fatty acid-producing gut microbiota is decreased in Parkinson\u2019s disease but not in rapid-eye-movement sleep behavior disorder. mSystems 5, 6 (2020).","DOI":"10.1128\/mSystems.00797-20"},{"key":"395_CR23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel, S. et al. Update of the MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 34, 1464\u20131470 (2019).","journal-title":"Mov. Disord."},{"key":"395_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. The \u03b1-Synuclein Origin and Connectome Model (SOC Model) of Parkinson\u2019s disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J. Parkinson\u2019s Dis. 11, 455\u2013474 (2021).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"395_CR25","doi-asserted-by":"crossref","unstructured":"Plassais, J. et al. Gut microbiome alpha-diversity is not a marker of Parkinson\u2019s disease and multiple sclerosis. Brain Commun. 3, 2 (2021).","DOI":"10.1093\/braincomms\/fcab113"},{"key":"395_CR26","doi-asserted-by":"publisher","unstructured":"Xie, A. et al. Bacterial butyrate in Parkinson\u2019s disease is linked to epigenetic changes and depressive symptoms. Mov. Disord. (2022). https:\/\/doi.org\/10.1002\/mds.29128.","DOI":"10.1002\/mds.29128"},{"key":"395_CR27","doi-asserted-by":"publisher","first-page":"103293","DOI":"10.1016\/j.ebiom.2021.103293","volume":"66","author":"S Deleu","year":"2021","unstructured":"Deleu, S., Machiels, K., Raes, J., Verbeke, K. & Vermeire, S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine 66, 103293 (2021).","journal-title":"EBioMedicine"},{"key":"395_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Park. Relat. Disord. 32, 66\u201372 (2016).","journal-title":"Park. Relat. Disord."},{"key":"395_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VTE Aho","year":"2021","unstructured":"Aho, V. T. E. et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol. Neurodegener. 16, 1\u201314 (2021).","journal-title":"Mol. Neurodegener."},{"key":"395_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"F Baert","year":"2021","unstructured":"Baert, F. et al. Parkinson\u2019s disease patients\u2019 short chain fatty acids production capacity after in vitro fecal fiber fermentation. npj Park. Dis. 7, 1\u201314 (2021).","journal-title":"npj Park. Dis."},{"key":"395_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1757-4749-5-23","volume":"5","author":"LR Lopetuso","year":"2013","unstructured":"Lopetuso, L. R., Scaldaferri, F., Petito, V. & Gasbarrini, A. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog. 5, 1\u20138 (2013).","journal-title":"Gut Pathog."},{"key":"395_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12915-019-0699-4","volume":"17","author":"JL Waters","year":"2019","unstructured":"Waters, J. L. & Ley, R. E. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. BMC Biol. 17, 1\u201311 (2019).","journal-title":"BMC Biol."},{"key":"395_CR33","doi-asserted-by":"crossref","unstructured":"Cao, H. et al. Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine. Sci. Rep. 7, 10322 (2017).","DOI":"10.1038\/s41598-017-10835-8"},{"key":"395_CR34","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2016.10.043","volume":"167","author":"MS Desai","year":"2016","unstructured":"Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339\u20131353.e21 (2016).","journal-title":"Cell"},{"key":"395_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/s11596-021-2464-5","volume":"41","author":"X Fang","year":"2021","unstructured":"Fang, X., Li, F. J. & Hong, D. J. Potential role of akkermansia muciniphila in Parkinson\u2019s disease and other neurological\/autoimmune diseases. Curr. Med. Sci. 41, 1172\u20131177 (2021).","journal-title":"Curr. Med. Sci."},{"key":"395_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Sci. (80-.) 352, 565\u2013569 (2016).","journal-title":"Sci. (80-.)"},{"key":"395_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3233\/JPD-161050","volume":"7","author":"K Knudsen","year":"2017","unstructured":"Knudsen, K. et al. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson\u2019s disease: a colon transit and volume study. J. Parkinsons. Dis. 7, 359\u2013367 (2017).","journal-title":"J. Parkinsons. Dis."},{"key":"395_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/mds.26866","volume":"32","author":"K Knudsen","year":"2017","unstructured":"Knudsen, K., Krogh, K., \u00d8stergaard, K. & Borghammer, P. Constipation in Parkinson\u2019s disease: subjective symptoms, objective markers, and new perspectives. Mov. Disord. 32, 94\u2013105 (2017).","journal-title":"Mov. Disord."},{"key":"395_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/ajg.2009.612","volume":"105","author":"RJ Saad","year":"2010","unstructured":"Saad, R. J. et al. Do stool form and frequency correlate with whole-gut and colonic transit results from a multicenter study in constipated individuals and healthy controls. Am. J. Gastroenterol. 105, 403\u2013411 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"395_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.5056\/jnm17022","volume":"23","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich, V., Patcharatrakul, T. & Gonlachanvit, S. Prediction of delayed colonic transit using Bristol stool form and stool frequency in Eastern constipated patients: a difference from the West. J. Neurogastroenterol. Motil. 23, 561\u2013568 (2017).","journal-title":"J. Neurogastroenterol. Motil."},{"key":"395_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12687-017-0318-4","volume":"8","author":"H K\u00e4\u00e4ri\u00e4inen","year":"2017","unstructured":"K\u00e4\u00e4ri\u00e4inen, H., Muilu, J., Perola, M. & Kristiansson, K. Genetics in an isolated population like Finland: a different basis for genomic medicine? J. Community Genet. 8, 319\u2013326 (2017).","journal-title":"J. Community Genet."},{"key":"395_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41588-020-00763-1","volume":"53","author":"A Kurilshikov","year":"2021","unstructured":"Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156\u2013165 (2021).","journal-title":"Nat. Genet."},{"key":"395_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-014-0087-z","volume":"12","author":"SJ Salter","year":"2014","unstructured":"Salter, S. J. et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87 (2014).","journal-title":"BMC Biol."},{"key":"395_CR44","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","volume":"79","author":"P Zimmermann","year":"2019","unstructured":"Zimmermann, P. & Curtis, N. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. J. Infect. 79, 471\u2013489 (2019).","journal-title":"J. Infect."},{"key":"395_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-021-00260-0","volume":"7","author":"SP van Kessel","year":"2021","unstructured":"van Kessel, S. P., Auvinen, P., Scheperjans, F. & El Aidy, S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease. npj Park. Dis. 7, 115 (2021).","journal-title":"npj Park. Dis."},{"key":"395_CR46","doi-asserted-by":"publisher","first-page":"e0217194","DOI":"10.1371\/journal.pone.0217194","volume":"14","author":"JG Choi","year":"2019","unstructured":"Choi, J. G., Huh, E., Kim, N., Kim, D. H. & Oh, M. S. High-throughput 16S rRNA gene sequencing reveals that 6-hydroxydopamine affects gut microbial environment. PLoS ONE 14, e0217194 (2019).","journal-title":"PLoS ONE"},{"key":"395_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fneur.2021.574529","volume":"12","author":"N Palacios","year":"2021","unstructured":"Palacios, N. et al. Effect of Levodopa initiation on the gut microbiota in Parkinson\u2019s disease. Front. Neurol. 12, 64 (2021).","journal-title":"Front. Neurol."},{"key":"395_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mdc3.12591","volume":"5","author":"C Halsband","year":"2018","unstructured":"Halsband, C., Zapf, A., Sixel-D\u00f6ring, F., Trenkwalder, C. & Mollenhauer, B. The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 5, 171\u2013176 (2018).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"395_CR49","doi-asserted-by":"crossref","unstructured":"Kennedy, M. S. & Chang, E. B. The microbiome: composition and locations. in Progress in Molecular Biology and Translational Science 176 1\u201342 (NIH Public Access, 2020).","DOI":"10.1016\/bs.pmbts.2020.08.013"},{"key":"395_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01811-3","volume":"20","author":"JM Boertien","year":"2020","unstructured":"Boertien, J. M. et al. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson\u2019s disease patients for the identification and validation of biomarkers for Parkinson\u2019s disease subtypes, progression and pathophysiology. BMC Neurol. 20, 245 (2020).","journal-title":"BMC Neurol."},{"key":"395_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00825-3","volume":"11","author":"EA Honkanen","year":"2021","unstructured":"Honkanen, E. A. et al. Sex correction improves the accuracy of clinical dopamine transporter imaging. EJNMMI Res. 11, 1\u20139 (2021).","journal-title":"EJNMMI Res."},{"key":"395_CR52","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov. Disord. 22, 1901\u20131911 (2007).","journal-title":"Mov. Disord."},{"key":"395_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"395_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-018-2262-7","volume":"19","author":"P Somervuo","year":"2018","unstructured":"Somervuo, P. et al. BARCOSEL: a tool for selecting an optimal barcode set for high-throughput sequencing. BMC Bioinforma. 19, 1\u20136 (2018).","journal-title":"BMC Bioinforma."},{"key":"395_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10\u201312 (2011).","journal-title":"EMBnet. J."},{"key":"395_CR56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"key":"395_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3501-4","volume":"18","author":"M Balvo\u010diute","year":"2017","unstructured":"Balvo\u010diute, M. & Huson, D. H. SILVA, RDP, Greengenes, NCBI and OTT - how do these taxonomies compare? BMC Genomics 18, 114 (2017).","journal-title":"BMC Genomics"},{"key":"395_CR58","doi-asserted-by":"publisher","first-page":"e61217","DOI":"10.1371\/journal.pone.0061217","volume":"8","author":"PJ McMurdie","year":"2013","unstructured":"McMurdie, P. J. & Holmes, S. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217 (2013).","journal-title":"PLoS ONE"},{"key":"395_CR59","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fmicb.2017.02224","volume":"8","author":"GB Gloor","year":"2017","unstructured":"Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V. & Egozcue, J. J. Microbiome datasets are compositional: and this is not optional. Front. Microbiol. 8, 2224 (2017).","journal-title":"Front. Microbiol."},{"key":"395_CR60","doi-asserted-by":"publisher","unstructured":"Anderson, M. J. Permutational Multivariate Analysis of Variance (PERMANOVA). in Wiley StatsRef: Statistics Reference Online 1\u201315 (American Cancer Society, 2017). https:\/\/doi.org\/10.1002\/9781118445112.stat07841.","DOI":"10.1002\/9781118445112.stat07841"},{"key":"395_CR61","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3389\/fmicb.2017.02114","volume":"8","author":"A Kaul","year":"2017","unstructured":"Kaul, A., Mandal, S., Davidov, O. & Peddada, S. D. Analysis of microbiome data in the presence of excess zeros. Front. Microbiol. 8, 2114 (2017).","journal-title":"Front. Microbiol."},{"key":"395_CR62","doi-asserted-by":"crossref","unstructured":"Mandal, S. et al. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb. Ecol. Heal. Dis. 26, (2015).","DOI":"10.3402\/mehd.v26.27663"},{"key":"395_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00395-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00395-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00395-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T20:04:46Z","timestamp":1665432286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00395-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00395-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.18.22270887","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.B. received an honorarium for writing an article for the magazine \u201cKinetic\u201d by Britannia Pharmaceuticals and owns exchange traded funds that might include stocks in medically related fields. K.M. grants from The Finnish Parkinson Foundation, Hospital District of Helsinki and Uusimaa and Maire Taponen Foundation. E.J. has received a grant from the Finnish Parkinson Foundation. E.P. has received consulting fees from Abbvie, Boston Scientific, Nordic Infucare and is consulting neurologist for patient insurance center of Finland. Speaker\u2019s honoraria from Abbott, Abbvie, and Nordic InfuCare. He is PI in Finland: International Adroit-study (Abbott DBS Registry of Outcomes for Indications over Time) 2021: Organized by Abbott. VK received consulting fees from Orion Pharma and Nordic Infucare AB, participated in advisory boards for Abbvie and Nordic Infucare AB, and received speaker\u2019s honoraria from Nordic Infucare AB, GE Healthcare and Abbvie. F.S. has received grants from The Academy of Finland, The Hospital District of Helsinki and Uusimaa, OLVI-Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, The Wilhelm and Else Stockmann Foundation, The Emil Aaltonen Foundation, The Yrj\u00f6 Jahnsson Foundation, Renishaw, and honoraria from AbbVie, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, and Biogen. F.S. is the founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics. T.v.L. has received grant support from the MJFF, the UMCG, Menzis, Weston Brain Institute, and the Dutch Brain Foundation. Consultancy fees were received from AbbVie, Britannia Pharm., Centrapharm and Neuroderm. Speaker fees were received from AbbVie, Britannia Pharm., and Eurocept. P.A.B.P., L.P., P.A., and F.S. have patents issued (FI127671B & US10139408B2) and pending (US16\/186,663 & EP3149205) that are assigned to NeuroBiome Ltd. Non-financial competing interests: E.P. is a member of the MDS Non-Motor Study Group. All other authors declare to have no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}